The new 6,400 m² facility will house cutting-edge equipment and advanced technologies that support the development, manufacture and testing of advanced therapy medicinal products (ATMPs) such as adenoviral and adeno-associated viral (AAV) therapies. It will also have dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture, Biovian announced.

The investment will increase Biovian’s existing manufacturing facility to a total area of 11,500 m². The company said that the additional space complements its existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector as well as microbial protein projects.

The expansion is expected to be completed in December 2024, with the new facility fully operational by 2025. The investment is expected to create 100 jobs in the region, in addition to Biovian's team of about 200 employees to date.

Antti Nieminen, CEO of Biovian, commented: “The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases."